Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle® in Postmenopausal Women
Status:
Completed
Trial end date:
2003-06-06
Target enrollment:
Participant gender:
Summary
This study is conducted in Europe. The aim of this study is to investigate the bleeding
profile after switch from Trisekvens® to Activelle® (1.0 mg estradiol / 0.5 mg norethisterone
acetate (NETA)).